JP2022525945A - 超粒子製剤 - Google Patents

超粒子製剤 Download PDF

Info

Publication number
JP2022525945A
JP2022525945A JP2021556581A JP2021556581A JP2022525945A JP 2022525945 A JP2022525945 A JP 2022525945A JP 2021556581 A JP2021556581 A JP 2021556581A JP 2021556581 A JP2021556581 A JP 2021556581A JP 2022525945 A JP2022525945 A JP 2022525945A
Authority
JP
Japan
Prior art keywords
superpartners
another example
payload
superpartner
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021556581A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022525945A5 (https=
Inventor
アンドリュー・ワイズ
ユーティエン・マ
フランク・カルソ
マティアス・ビョルンマルム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Melbourne
Original Assignee
University of Melbourne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2019900910A external-priority patent/AU2019900910A0/en
Application filed by University of Melbourne filed Critical University of Melbourne
Publication of JP2022525945A publication Critical patent/JP2022525945A/ja
Publication of JP2022525945A5 publication Critical patent/JP2022525945A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5052—Proteins, e.g. albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/02—Details
    • A61N1/04—Electrodes
    • A61N1/05—Electrodes for implantation or insertion into the body, e.g. heart electrode
    • A61N1/0526—Head electrodes
    • A61N1/0541—Cochlear electrodes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/36036—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation of the outer, middle or inner ear
    • A61N1/36038—Cochlear stimulation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/48—Nerve growth factor [NGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/04—Enzymes or microbial cells immobilised on or in an organic carrier entrapped within the carrier, e.g. gel or hollow fibres
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2462—Lysozyme (3.2.1.17)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01017—Lysozyme (3.2.1.17)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Psychology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2021556581A 2019-03-19 2020-03-19 超粒子製剤 Pending JP2022525945A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2019900910 2019-03-19
AU2019900910A AU2019900910A0 (en) 2019-03-19 Improved supraparticles II
PCT/AU2020/050260 WO2020186304A1 (en) 2019-03-19 2020-03-19 Supraparticle formulations

Publications (2)

Publication Number Publication Date
JP2022525945A true JP2022525945A (ja) 2022-05-20
JP2022525945A5 JP2022525945A5 (https=) 2023-04-03

Family

ID=72518918

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021556581A Pending JP2022525945A (ja) 2019-03-19 2020-03-19 超粒子製剤

Country Status (6)

Country Link
US (1) US12551450B2 (https=)
EP (1) EP3941442A4 (https=)
JP (1) JP2022525945A (https=)
CN (1) CN114040753A (https=)
AU (1) AU2020242921B2 (https=)
WO (1) WO2020186304A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117065055B (zh) * 2022-05-24 2025-08-29 天津医科大学第二医院 一种核壳型纳米酶探针及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11509167A (ja) * 1994-11-01 1999-08-17 ドンクーク ファーマシューティカル カンパニー リミテッド 歯周炎治療のための徐放出型生分解性製剤
JP2010516246A (ja) * 2007-01-19 2010-05-20 ザ アイムス カンパニー 安定化した感受性成分の組成物及び安定化方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4468498A (en) 1980-06-12 1984-08-28 Rohm And Haas Company Sequential heteropolymer dispersion and a particulate materal obtainable therefrom, useful in coating compositions as a thickening and/or opacifying agent
US4434153A (en) 1982-03-22 1984-02-28 Alza Corporation Drug delivery system comprising a reservoir containing a plurality of tiny pills
US5157084A (en) 1990-10-12 1992-10-20 The Dow Chemical Company Process of making hollow polymer latex particles
US5521253A (en) 1990-10-12 1996-05-28 The Dow Chemical Company Hollow polymer latex particles
SE9101853D0 (sv) * 1991-06-17 1991-06-17 Jonas Wadstroem Improved tissue ashesive
JP4116683B2 (ja) * 1997-02-28 2008-07-09 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 徐放性局所送達製剤
WO2003065881A2 (en) * 2002-02-06 2003-08-14 Orbus Medical Technologies Inc. Medical device with coating that promotes endothelial cell adherence and differentiation
WO2006037160A1 (en) 2004-10-05 2006-04-13 The University Of Melbourne Porous polyelectrolyte materials
CN100558403C (zh) * 2006-10-23 2009-11-11 中国科学院理化技术研究所 双壳层药物缓控释载体材料及其制备方法和用途
CN103467755B (zh) * 2013-09-18 2015-06-17 薛巍 一种药物缓释水凝胶及其制备方法与用途
WO2018013928A1 (en) * 2016-07-14 2018-01-18 University Hospitals Cleveland Medical Center Compositions and methods for collagen-based sutures and antibacterial coatings
CN108384031B (zh) * 2017-06-27 2020-10-27 中南民族大学 一种缓释水凝胶载体材料的制备方法和应用
CN107375196B (zh) * 2017-07-26 2020-02-07 暨南大学 一种含儿茶酚基天然多糖复合水凝胶载体及其制备方法
CN107865822A (zh) * 2017-08-25 2018-04-03 中南民族大学 一种掺入纳米介孔二氧化硅的水凝胶药物缓释载体材料的制备方法和应用
AU2018337076B2 (en) * 2017-09-20 2024-09-26 The Bionics Institute Of Australia Method of treatment

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11509167A (ja) * 1994-11-01 1999-08-17 ドンクーク ファーマシューティカル カンパニー リミテッド 歯周炎治療のための徐放出型生分解性製剤
JP2010516246A (ja) * 2007-01-19 2010-05-20 ザ アイムス カンパニー 安定化した感受性成分の組成物及び安定化方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Fibrin-based microsphere reservoirs for delivery of neurotrophic factors to the brain", NANOMEDICINE, vol. 10, NO. 5, JPN6024003481, 2015, pages 765 - 783, ISSN: 0005430992 *
"Gel-Mediated Electrospray Assembly of Silica Supraparticles for Sustained Drug Delivery", ACS APPLIED MATERIALS & INTERFACES, vol. Volumne 10, issue 37, JPN6024003482, 2018, pages 31019 - 31031, ISSN: 0005430991 *

Also Published As

Publication number Publication date
EP3941442A4 (en) 2022-12-21
US12551450B2 (en) 2026-02-17
US20220168228A1 (en) 2022-06-02
CN114040753A (zh) 2022-02-11
AU2020242921B2 (en) 2025-04-03
WO2020186304A1 (en) 2020-09-24
EP3941442A1 (en) 2022-01-26
AU2020242921A1 (en) 2021-10-07

Similar Documents

Publication Publication Date Title
US20250205308A1 (en) Supraparticles
US7785617B2 (en) Porous matrix comprising cross-linked particles
Shultz et al. Hydrogel-based local drug delivery strategies for spinal cord repair
US11213490B2 (en) Encapsulation-free controlled protein release system
US20130196915A1 (en) Affinity hydrogels for controlled protein release
CN103237565A (zh) 用于基于材料的细胞疗法的可注射的成孔水凝胶
Mondalek et al. Enhanced angiogenesis of modified porcine small intestinal submucosa with hyaluronic acid‐poly (lactide‐co‐glycolide) nanoparticles: From fabrication to preclinical validation
Liu et al. Hierarchically porous calcium–silicon nanosphere-enabled co-delivery of microRNA-210 and simvastatin for bone regeneration
Xu et al. Delivery of plasmid IGF‐1 to chondrocytes via cationized gelatin nanoparticles
Li et al. An injectable, self-healing and degradable hydrogel scaffold as a functional biocompatible material for tissue engineering applications
CN110124103B (zh) 一种用于组织修复的活性物质缓释材料体系及其制备方法
Negron et al. Non-adhesive and highly stable biodegradable nanoparticles that provide widespread and safe transgene expression in orthotopic brain tumors
Ji et al. 3D printing cervical implant scaffolds incorporated with drug-loaded carboxylated chitosan microspheres for long-term anti-HPV protein delivery
JP2012517430A (ja) 外部からの合図によるオンデマンドで可逆的な薬物放出
JP2022525945A (ja) 超粒子製剤
KR101685295B1 (ko) 다중 약물 탑재 스캐폴드 및 이의 용도
Lee et al. Carboxymethyl cellulose‐polylactic acid particles for inhibiting anoikis and enhancing wound healing efficacy of human mesenchymal stem cells
KR20160036737A (ko) 성장인자를 함유한 생분해용 폴리머-쉘화된 메소포러스 나노구가 삽입된 치료용 폼 스캐폴드
CN117138058A (zh) 用于修复骨缺损的脂质体、水凝胶及制备方法与应用
CN114126677B (zh) 可交联水凝胶组合物
Jose et al. Alginate Hydrogel and Aerogel
Li et al. Three-dimensional-printed hydroxyapatite/nanoclay/polycaprolactone composite scaffold for immunomodulation and bone defect repair
Jiang et al. Dual‐Responsive Core‐Shell Nanocapsules Orchestrate a" Clearance–Then–Repair" Microenvironment for Tracheal Reconstruction
Carrêlo et al. Injectable Composite Systems Based on Microparticles in Hydrogels for Bioactive Cargo Controlled Delivery. Gels 2021, 7, 147

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230317

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230317

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240110

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240205

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240502

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241007